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A recent paper reported that Aβ oligomer causes neuronal cell death through the phosphatidylinositol-3-OH kinase (PI3K)-
Akt-mTOR signaling pathway. Intraneuronal Aβ, a main pathological ﬁnding of Alzheimer’s disease (AD), is also known as
inhibiting activation of Akt. This study aims to investigate whether single nucleotide polymorphisms (SNPs) of the Akt1 gene
are associated with AD. SNPs genotyped using TaqMan technology was analyzed using a case-control study design. Our case-
control dataset consisted of 180 AD patients and 130 age-matched controls. Although two SNPs showed superﬁcial positive,
Hardy-Weinberg equilibrium (HWE) tests, and linkage disequilibrium (LD) analyses suggested that genetic regions of the gene
are highly polymorphic. We failed to detect any synergetic association among Akt1 polymorphisms, Apolipoprotein E (APO E),
and AD. Further genetic studies are needed to clarify the relationship between the Akt1 and AD.
1.Introduction
The main pathological feature of Alzheimer’s disease (AD) is
the senile plaque containing aggregated Amyloid β peptide
(Aβ). Three genes have been identiﬁed as causative genes
in familial AD; the amyloid precursor protein (APP),
presenilin-1, and presenilin-2 genes. Apolipoprotein E (APO
E) is recognized as a genetic risk factor for familial and
sporadic AD [1]. In addition, variants of the sortilin-related
receptor 1 (SORL1) gene have also been associated with
the disease [1, 2]. The evidence from SORL1 suggested
that intraneuronal Aβ is signiﬁcant in early pathogenesis
for AD. Recent ﬁndings showed that Aβ oligomer is more
toxic for neuronal cell [3, 4]. There is widening recog-
nition that the phosphatidylinositol-3-OH kinase (PI3K)-
Akt-mTOR signaling pathway is directly aﬀected by Aβ
and especially Aβ oligomer modulate cell survival through
PI3K-Akt pathway [3, 5–7]. An impaired insulin-mediated
signal transduction is one of the pathological features
of neurodegenerative diseases [8]. Epidemiological studies
note that type II diabetes is risk factor for late-onset AD
[9]. Insulin dysfunction might be associated with Aβ and
tangles [10, 11]. Intraneuronal Aβ inhibits insulin receptors
signaling in neurons by interfering with the association
between Akt1 to preclude Akt1 activation [12]. In AD brains,
level of PI3K-Akt-mTOR would be decreased [8]. Thus
current reports revealed that the dysfunction of PI3K-Akt-
mTOR system aﬀect AD pathology [9]. Although genetic
variability of PI3K has been reported to aﬀect the risk for
AD [13], there are few genetic researches about Akt and AD.
In this study, the association between six single nucleotide
polymorphisms (SNPs) covering the Akt1 gene and Japanese
sporadic AD was investigated.
2.MaterialsandMethods
DNA was extracted from white blood cells using a standard
method. Our sporadic Japanese AD cases (n = 180,
Male:Female = 79:101) were obtained from department
of psychiatry, Juntendo university hospital, Tokyo, Japan
and department of psychiatry, Juntendo Koshigaya hospital,
SaitamaJapan.ThemeanageoftheADgroup(67.4,S.D.6.2)
was not signiﬁcantly diﬀerent from that of the control group2 International Journal of Alzheimer’s Disease
Table 1: Genotypic frequencies of SNPs of the Akt1 gene.
SNP Location Genotype AD Controls P value HWE P value
A/A 3 3
rs113021411 intron 1 A/C 33 45 0.002∗ AD: 0.93
C/C 142 81 Controls: 0.68
C/C 77 22
rs2494746 intron 3 C/G 72 85 0.00002∗ AD: 0.52
G/G 29 22 Controls: 0.04∗
C/C 78 22
rs2494743 intron 3 C/T 71 85 0.00001∗ AD: 0.47
T/T 29 22 Controls: 0.04∗
A/A 27 20
rs2494738 intron 3 A/G 79 68 0.3 AD: 0.93
G/G 71 41 Controls: 0.91
A/A 174 126
rs3730344 intron 6 A/G 4 3 0.99 AD: 0.99
G/G 0 0 Controls: 0.99
A/A 151 114
rs7140735 intron 13 A/G 27 13 0.17 AD: 0.88
G/G 0 1 Controls: 0.99
P∗ < 0.05: Statistically signiﬁcant (Fisher’s exact probabilities test).
Table 2: Linkage disequilibrium (D  value) between SNPs.
rs1130214 rs2494746 rs2494743 rs2494738 rs3730344 rs7140735
rs1130214 (I1)
rs2494746 (I3) 1
rs2494743 (I3) 0.9728 0.9933
rs2494738 (I3) 0.0554 −0.4329 −0.4273
rs3730344 (I6) −0.9999 1 1 0.3476
rs7140735 (I13) 0.2407 0.2742 0.2838 −11
(64.4, S.D. 6.7) by the Fisher’s exact probabilities test. All the
AD cases were diagnosed according to the NINCDS-ADRDA
criteria, and none had familial history of AD. The control
cases (n = 130, Male:Female = 63:67) were obtained from
healthy volunteers from among staﬀ of our hospital with
no history of dementia or other neuropsychiatric diseases.
The purpose and signiﬁcance of this study were explained
in detail to each patient and his/her family, and all subjects
provided their informed consent. The study protocol was
approvedbytheEthicscommittee oftheJuntendoUniversity
School of Medicine.
Information on the single nucleotide polymorphisms
SNPs was obtained from the SNP database (dbSNP) estab-
lished by the National Center for Biotechnology Infor-
mation. We selected the SNPs to cover the entire gene,
including tagging SNPs. The chosen SNPs were validated,
according to the dbSNP and have minor allele frequencies
(MAF) greater than 5%. Six SNPs of the Akt1 gene were
genotyped using TaqMan technology on an ABI7500 system
(Applied Biosystems, Calif, USA). All probes and primers
were designed by the Assay-by-Design TM service of Applied
Biosystems. A standard PCR reaction was carried out using
the TaqMan universal PCR master mix reagent kit in a 10μL
volume. Hardy-Weinberg equilibrium (HWE) tests were
carried out for all SNPs for both cases and controls. APO
E genotypes for all the samples were determined according
to a previous report [14]. Diﬀerences in the genotypic
frequencies were evaluated using a case-control study design
and applying the Fisher’s exact probabilities test.
Linkage disequilibrium (LD) between the SNPs as well as
ahaplotypeanalysiswasperformedusingSNPAlyseversion5
(DYNACOM,Yokohama,Japan).LD,denotedasD
 ,wascal-
culated from the haplotype frequency using the expectation-
maximization algorithm. SNPs were considered to be in LD
if D
  was greater than 0.75. A case-control haplotype analysis
was performed using a permutation method to obtain
the empirical signiﬁcance. The global P values represent
the overall signiﬁcance of the observed versus expected
frequencies of all the haplotypes considered together using
the chi-squared test. The individual haplotypes were tested
for association by grouping all others together and applying
the chi-squared test with ldf. P values were calculated on
the basis of 10,000 replications. All P values reported are
two tailed, and statistical signiﬁcance was deﬁned as <0.05.
Logistic regression analyses were performed to estimate the
relationship among onset of AD, APO E status, and sixInternational Journal of Alzheimer’s Disease 3
Table 3: A case-control haplotype analysis for the 6 Akt1 SNPs.
Haplotype Overall AD Control Chi-square P value Permutation P value
C-C-C-A-A-A 0.3067 0.3165 0.2969 0.2694 0.6038 0.603
C-C-C-G-A-A 0.2401 0.2818 0.1779 8.8385 2.95E −03 0.008∗
C-G-T-G-A-A 0.2378 0.2236 0.26 1.0827 0.2981 0.324
A-G-T-A-A-A 0.0658 0.0449 0.0919 5.4284 0.0198 0.044∗
A-G-T-G-A-A 0.0549 0.0347 0.0856 7.2736 7.00E −03 0.028∗
Rare haplotypes with frequencies less than 5% are not shown.
Each nucleotide on the haplotypes represents the SNPs in the following order from left to right: rs1130214 to rs7140735.
P∗ < 0.05: Statistically signiﬁcant.
SNPs using SPSS software ver. 17.0 for Windows; (Chicago,
Ill., USA). A P value of <0.05 was considered statistically
signiﬁcant.
3. Results andDiscussion
Our sample set has the power to detect an odds ratio of at
least1.40,assumingasigniﬁcancelevelof0.05,powerof0.70,
and an exposure frequency of 0.25 in the controls. Although
four SNPs were found to be in HWE, controls of rs2494746
and rs2494743 were not in HWE marginally. Genotypic
distribution of the two polymorphisms showed signiﬁcant
diﬀerence between our cases and controls (Table 1). Other
four SNPs Linkage disequilibrium examination showed
strong LD from rs1130214 to rs2494743 and from rs3730344
to rs7140735 (Table 2). The frequency of the C-C-C-G-
A-A haplotype was signiﬁcantly higher in the AD group
compared to controls (Table 3). Other two rare haplotypes
also showed marginal association.
To date, this is the ﬁrst study to clarify genetic associa-
tions between common SNPs of the Akt1 gene and AD. We
found that two SNPs rs2494746 and rs2494743 studied here
with Japanese population werenot in HWE. Haplotype anal-
ysis seemed to be positive superﬁcially. Multiple regression
analysis suggested that six SNPs of the Akt1 gene did not
associate with the risk for AD and logistic regression analysis
for the Akt1 SNPs, APO E and the onset of AD showed no
synergetic association (data not shown). SNPs which were
not in HWE make us suppose that the regions around such
SNPs are highly polymorphic. These SNPs would be triallelic
SNPs, or there are large deletions or insertions generally.
Since we conﬁrmed that the two SNPs are biallelic, potential
large deletion or insertion might exist in the Akt1 gene.
Our LD analyses also suggested that the gene consists of
two distinct LD blocks. Rs2494738 was thought not to be
involved in the two LD blocks. SNPs which are not in HWE
with homozygote excess sometimes show positive generally.
These SNPs suggest that there are potential polymorphisms
including insertion or deletion associated with the disease.
Reviewing our raw genotyping data, heterozygotes of control
cases of those two SNPs are more frequent than estimated.
Thus we guess the SNPs studied here did not aﬀect the
disease.
Previous genetic studies for schizophrenic patients are
in debate [15–18]. An original report identiﬁed Akt1 as
a potential schizophrenia susceptibility gene in families of
European origins [19]. The additional multi-SNP haplotype
analysis showed that speciﬁc haplotype is associated with
lower Akt1 protein levels [20]. Controversial results have
been issued for Japanese schizophrenic patients and Akt1
[15, 16, 21]. The detailed LD analysis from these Japanese
studiessuggestedthattherearetwoapparentLDblocksinthe
gene [21, 22]. These ﬁndings accord with our results. Thus
the Akt1 gene is highly polymorphic, and functional SNPs
might aﬀect Akt1 levels potentially. We believe that the small
size of our dataset may account for the negative results. Our
dataset could detect the genetic association between APO E4
and AD. If the SNPs of the Akt1 gene aﬀect the onset of AD,
the eﬀects would be smaller than those of APO E4. Previous
studies and our ﬁndings revealed that the regions of the Akt1
gene are highly polymorphic for Japanese population.
4. Conclusion
Although our pilot study could not show a genetic associa-
tion between Akt1 and AD, PI3K-Akt-mTOR system has an
important role for pathophysiology of AD. Denser SNPing
studieswouldbeneededforclarifyingthegeneticassociation
between Akt1 and AD. Since the relationship between Akt1
and AD remains inconclusive, a meta-analysis would be
performed in the future.
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